Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.
SMI 10'268 1.4%  SPI 13'166 1.5%  Dow 28'726 -1.7%  DAX 12'114 1.2%  Euro 0.9672 1.0%  EStoxx50 3'318 1.2%  Gold 1'661 0.0%  Bitcoin 19'178 0.6%  Dollar 0.9886 0.1%  Öl 87.9 -1.1% 

Aktionärsstruktur

Inhaber in %
Freefloat 95.25
Investor AB (Investment Company) 3.33
Government Pension Fund - Global (The) 2.17
Vanguard Health Care Fund 1.34
Vanguard Total International Stock Index Fund 1.32
American Funds Income Fund of America 0.79
Goldman Sachs GQG Partners International Opportunities Fund 0.74

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2017 2018 2019 2020 2021
Personal am Ende des Jahres 61'100 64'400 70'600 76'100 83'100
Umsatz pro Mitarbeiter in Mio. EUR 0.29 0.26 0.27 0.28 0.33

Bilanz (in Mio. EUR) - Aktiva

2017 2018 2019 2020 2021
Summe Umlaufvermögen 9'524 12'184 11'748 14'298 19'376
Summe Anlagevermögen 24'223 24'797 23'668 26'337 51'718
Summe Aktiva 46'833 47'622 46'331 48'816 77'790

Bilanz (in Mio. EUR) - Passiva

2017 2018 2019 2020 2021
Gesamtverschuldung/ -verbindlichkeiten 13'164 15'007 13'759 14'909 22'726
Summe Fremdkapital 34'531 36'595 35'313 37'376 48'784
Summe Eigenkapital 12'302 11'027 11'018 11'440 29'006
Summe Passiva 46'833 47'622 46'331 48'816 77'790

Adresse

Cambridge Biomedical Campus, CB2 0AA Cambridge
Telefon +44 (20) 3749-5000
Fax +44 (12) 2335-2858
URL http://www.astrazeneca.com

Management

Adrian Charles Noel Kemp
Secretary
Ahmed M. Hamdy
Member
Andreas Rummelt
Non-Executive Director
Aradhana Sarin
Chief Financial Officer & Executive Director
David Fredrickson
Executive Vice President-Oncology Business Unit
Deborah DiSanzo
Independent Non-Executive Director
Diana Layfield
Non-Executive Director
Euan A. Ashley
Non-Executive Director
Helen MacPhee
Vice President
Henry D. Cremisi
Medical Director
Iskra Reic
Executive Vice President-Europe & Canada
Jeffrey Pott
Chief Human Resources Officer & General Counsel
Jonathan Thomas Charles Slade
Group Treasurer
Katarina Ageborg
Chief Compliance Officer & EVP-Sustainability
Kevin G. Lokay
Head-U.S. Immuno-oncology
Leif Valdemar Johansson
Non-Executive Chairman
Marc Pierre Jean Dunoyer
Chief Strategy Officer
Marcus Wallenberg
Independent Non-Executive Director
Margareta Elisabeth Björk
Senior VP & Head-Late-stage Development
Menelas NICOLAS Pangalos
EVP-Biopharmaceuticals Research & Development
Michel Demaré
Chairman-Designate
Nazneen Rahman
Independent Non-Executive Director
Pam P. Cheng
Executive VP-Operations & Information Technology
Pascal Soriot
Chief Executive Officer & Executive Director
Philip Arthur John Broadley
Senior Independent Non-Executive Director
Regina Fritsche Danielson
SVP, Head-Research & Early Development
Ruud Dobber
Executive VP-Biopharmaceuticals Business
Sarah Miksinski
Senior Director-Global Regulatory Affairs
Sherilyn D. McCoy
Independent Non-Executive Director
Sjoerd Hubben
Vice President-Global Government Affairs & Policy
Susan Mary Galbraith
Executive VP-Oncology Research & Development
Tony Mok
Independent Non-Executive Director
Tyrell J. Rivers
Executive Director-Corporate Development

Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen